UK Biobank (core renewal)
Lead Research Organisation:
UK Biobank
Department Name: UNLISTED
Abstract
UK Biobank is supported by The Wellcome Trust, The National Institute of Health Research, The Medical Research Council, The British Heart Foundation and Cancer Research UK. The figures presented on this record represent the Medical Research Council funding contribution only with some additional UKRI Infrastructure funds in addition.
UK Biobank is a prospective study of 500,000 men and women aged 40-69 years at the point of recruitment (2006-10). The study has collected extensive phenotypic and genotypic detail about its participants, including data from questionnaires, physical measures, sample assays, accelerometery, imaging, genome-wide genotyping and long-term longitudinal follow-up for a wide range of health-related outcomes. The resource is regularly augmented with additional data and is available to academic or commercial researchers world-wide to use for any type of health-related research that is in the public interest. It has been established primarily for the conduct of prospective studies investigating the relevance of a wide range of exposures to health outcomes that occur during long-term follow-up. The ongoing identification and adjudication of increasing numbers of incident cases of the commoner conditions in the resource will support extensive and powerful research into their determinants and the range of diseases that can be studied reliably will widen as the numbers of incident events of different types increase during follow-up over the next 5-10 year period. As a result, UK Biobank provides researchers from around the world with greater opportunities to better understand early disease stages and their diagnosis, and can support the development of new treatments for diseases of mid-to-later life.
UK Biobank is a prospective study of 500,000 men and women aged 40-69 years at the point of recruitment (2006-10). The study has collected extensive phenotypic and genotypic detail about its participants, including data from questionnaires, physical measures, sample assays, accelerometery, imaging, genome-wide genotyping and long-term longitudinal follow-up for a wide range of health-related outcomes. The resource is regularly augmented with additional data and is available to academic or commercial researchers world-wide to use for any type of health-related research that is in the public interest. It has been established primarily for the conduct of prospective studies investigating the relevance of a wide range of exposures to health outcomes that occur during long-term follow-up. The ongoing identification and adjudication of increasing numbers of incident cases of the commoner conditions in the resource will support extensive and powerful research into their determinants and the range of diseases that can be studied reliably will widen as the numbers of incident events of different types increase during follow-up over the next 5-10 year period. As a result, UK Biobank provides researchers from around the world with greater opportunities to better understand early disease stages and their diagnosis, and can support the development of new treatments for diseases of mid-to-later life.
Technical Summary
The UK Biobank resource has been established primarily for the conduct of prospective studies investigating the relevance of a wide range of exposures to health outcomes that occur during long-term follow-up. There are now sufficient numbers of incident cases of the commoner conditions to support extensive and powerful research into their determinants.
There is regular augmentation of UK Biobank’s capability for effective use as a prospective resource by the widest possible range of researchers. This activity has included: streamlining resource access management systems; imaging assessments; an agile response to the SARS-2 Covid pandemic; ‘omics; whole genome sequencing and turning biological samples into genotypic and biomarker data to make the resource more accessible to researchers studying a wide range of different conditions.
During the next few years, it is intended to develop UK Biobank as a UK national infrastructure and the resource will move to new premises at the University of Manchester where sample throughput will be accelerated with new robotics and freezer systems, making more large scale studies possible. UK Biobank will make increasing amounts of genotype and biomarker data available. It will seek to extend cohort-wide record linkage to primary care health; develop other linkages relevant to health; complete imaging assessments on close to 100,000 participants, including repeat imaging on a subset; develop and implement further enhancements (such as metabolomics) and introduce changes relating to participant involvement and to address equality diversity and inclusion. Communications will be expanded to a wider audience to help ensure that researchers from around the world are well informed about UK Biobank’s enhanced capabilities in order to maximise suitable use of the resource over the next few years.
There is regular augmentation of UK Biobank’s capability for effective use as a prospective resource by the widest possible range of researchers. This activity has included: streamlining resource access management systems; imaging assessments; an agile response to the SARS-2 Covid pandemic; ‘omics; whole genome sequencing and turning biological samples into genotypic and biomarker data to make the resource more accessible to researchers studying a wide range of different conditions.
During the next few years, it is intended to develop UK Biobank as a UK national infrastructure and the resource will move to new premises at the University of Manchester where sample throughput will be accelerated with new robotics and freezer systems, making more large scale studies possible. UK Biobank will make increasing amounts of genotype and biomarker data available. It will seek to extend cohort-wide record linkage to primary care health; develop other linkages relevant to health; complete imaging assessments on close to 100,000 participants, including repeat imaging on a subset; develop and implement further enhancements (such as metabolomics) and introduce changes relating to participant involvement and to address equality diversity and inclusion. Communications will be expanded to a wider audience to help ensure that researchers from around the world are well informed about UK Biobank’s enhanced capabilities in order to maximise suitable use of the resource over the next few years.
Organisations
People |
ORCID iD |
Rory Collins (Principal Investigator) |
Publications
Zhang H
(2023)
Assessing the joint effects of mitochondrial function and human behavior on the risks of anxiety and depression.
in Journal of affective disorders
Zhang H
(2021)
Meat consumption and risk of incident dementia: cohort study of 493,888 UK Biobank participants
in The American Journal of Clinical Nutrition
Zhang J
(2021)
The association between blood groups and COVID-19 infection: a study from the UK Biobank.
in Journal of internal medicine
Zhang J
(2023)
Water and adult eczema: the hard truth?
in The British journal of dermatology
Zhang J
(2022)
Habitual fish oil supplementation and the risk of incident atrial fibrillation: findings from a large prospective longitudinal cohort study.
in European journal of preventive cardiology
Zhang K
(2021)
Causal Associations Between Blood Lipids and COVID-19 Risk: A Two-Sample Mendelian Randomization Study
in Arteriosclerosis, Thrombosis, and Vascular Biology
Zhang L
(2018)
Automatic Assessment of Full Left Ventricular Coverage in Cardiac Cine Magnetic Resonance Imaging with Fisher Discriminative 3D CNN.
in IEEE transactions on bio-medical engineering
Zhang L
(2022)
Inflammation subtypes in psychosis and their relationships with genetic risk for psychiatric and cardiometabolic disorders
in Brain, Behavior, & Immunity - Health
Zhang L
(2021)
Joint Genome-Wide Association Analyses Identified 49 Novel Loci For Age at Natural Menopause.
in The Journal of clinical endocrinology and metabolism
Zhang LP
(2022)
Relationship between lipids and sleep apnea: Mendelian randomization analysis.
in World journal of clinical cases
Zhang M
(2022)
Causal associations of circulating adiponectin with cardiometabolic diseases and osteoporotic fracture.
in Scientific reports
Zhang M
(2022)
Exploring the association between birthweight and breast cancer using summary statistics from a perspective of genetic correlation, mediation, and causality.
in Journal of translational medicine
Zhang MJ
(2022)
Polygenic enrichment distinguishes disease associations of individual cells in single-cell RNA-seq data.
in Nature genetics
Zhang N
(2021)
Interaction between genetic predisposition, smoking, and dementia risk: a population-based cohort study.
in Scientific reports
Zhang P
(2022)
Regular proton pump inhibitor use and incident dementia: population-based cohort study.
in BMC medicine
Zhang Q
(2021)
Improved genetic prediction of complex traits from individual-level data or summary statistics.
in Nature communications
Zhang R
(2022)
Novel disease associations with schizophrenia genetic risk revealed in ~400,000 UK Biobank participants.
in Molecular psychiatry
Zhang R
(2022)
A Large-Scale Genome-Wide Gene-Gene Interaction Study of Lung Cancer Susceptibility in Europeans With a Trans-Ethnic Validation in Asians.
in Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Zhang S
(2023)
Exposure to Air Pollution during Pre-Hypertension and Subsequent Hypertension, Cardiovascular Disease, and Death: A Trajectory Analysis of the UK Biobank Cohort.
in Environmental health perspectives
Zhang S
(2023)
Association of Retinal Age Gap and Risk of Kidney Failure: A UK Biobank Study.
in American journal of kidney diseases : the official journal of the National Kidney Foundation
Zhang T
(2022)
ezQTL: A Web Platform for Interactive Visualization and Colocalization of QTLs and GWAS Loci.
in Genomics, proteomics & bioinformatics
Zhang W
(2022)
Shared brain and genetic architectures between mental health and physical activity.
in Translational psychiatry
Zhang WB
(2021)
The antagonistic pleiotropy of insulin-like growth factor 1.
in Aging cell
Zhang X
(2022)
Effect of proton pump inhibitors on the risk of chronic kidney disease: A propensity score-based overlap weight analysis using the United Kingdom Biobank
in Frontiers in Pharmacology
Zhang X
(2021)
Phenome-wide association study (PheWAS) of colorectal cancer risk SNP effects on health outcomes in UK Biobank
in British Journal of Cancer
Zhang X
(2022)
Large-scale genomic analyses reveal insights into pleiotropy across circulatory system diseases and nervous system disorders.
in Nature communications
Zhang X
(2022)
Association between dual sensory impairment and risk of mortality: a cohort study from the UK Biobank.
in BMC geriatrics
Zhang X
(2022)
Gender-specific association between the regular use of statins and the risk of irritable bowel syndrome: A population-based prospective cohort study.
in Frontiers in pharmacology
Zhang X
(2022)
Association of Visual Health With Depressive Symptoms and Brain Imaging Phenotypes Among Middle-Aged and Older Adults.
in JAMA network open
Zhang X
(2022)
Plasma metabolomic profiles of dementia: a prospective study of 110,655 participants in the UK Biobank.
in BMC medicine
Zhang X
(2022)
Correction: Association between dual sensory impairment and risk of mortality: a cohort study from the UK Biobank.
in BMC geriatrics
Zhang XR
(2022)
Glucosamine use, smoking and risk of incident chronic obstructive pulmonary disease: a large prospective cohort study.
in The British journal of nutrition
Zhang Y
(2021)
Birth Weight and Adult Obesity Index in Relation to the Risk of Hypertension: A Prospective Cohort Study in the UK Biobank.
in Frontiers in cardiovascular medicine
Zhang Y
(2022)
Evidence of a Causal Relationship Between Vitamin D Status and Risk of Psoriasis From the UK Biobank Study.
in Frontiers in nutrition
Zhang Y
(2022)
NUMBER OF CHILDREN AND RISK OF ALZHEIMER'S DISEASE AND DEMENTIA: EVIDENCE FROM THE UK BIOBANK
in Innovation in Aging
Zhang Y
(2023)
Gender differences in the association between parity and cognitive function: Evidence from the UK biobank.
in Social science & medicine (1982)
Zhang Y
(2022)
Association of cardiovascular health with diabetic complications, all-cause mortality, and life expectancy among people with type 2 diabetes.
in Diabetology & metabolic syndrome
Description | Impact of clinically silent atrial fibrillation on cerebrovascular disease and cognitive decline in the UK Biobank Imaging Cohort |
Amount | £2,474,260 (GBP) |
Funding ID | RG/18/6/33576 |
Organisation | British Heart Foundation (BHF) |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 06/2019 |
End | 06/2024 |
Description | UK Biobank - The Repeat Imaging Project |
Amount | £2,500,000 (GBP) |
Funding ID | R39738/CN039 |
Organisation | MRC Dementias Platform UK |
Sector | Academic/University |
Country | United Kingdom |
Start | 03/2019 |
End | 01/2023 |
Description | UK Biobank - Whole genome sequencing of 50,000 UKB participants |
Amount | £30,000,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 03/2018 |
End | 03/2020 |
Description | UK Biobank- Expansion of the UKB imaging to a 4th centre and repeat imaging assessment of 10,000 participants |
Amount | £8,500,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 03/2018 |
End | 12/2022 |
Description | UK Biobank Scientific Conference |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Public/other audiences |
Results and Impact | The UK Biobank Scientific Symposium included presentations about the successes and future plans of the UK Biobank. It took place on 21 June 2018 in London |
Year(s) Of Engagement Activity | 2018 |
Description | UK Biobank participant imaging event |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Study participants or study members |
Results and Impact | UK Biobank for participants of the imaging work |
Year(s) Of Engagement Activity | 2021 |
Description | UKBiobank participant events - 2014 - 2019 |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Study participants or study members |
Results and Impact | UKB Biobank participants regularly attend events aimed at informing them about the work being undertaken with their data. Usually, the events last a few hours and include an overview from the chief scientist and two talks from scientists that have used UKB data. From 2014 - 2020 over 4,000 participants have taken part in events in Edinburgh (4), Manchester (4), Nottingham, Leeds, Cardiff (2), Newcastle (5), Glasgow (2), Bristol (2) and Reading(4). They are often over-subscribed and participants leave these events wishing to seek more information and support he programme in new ways (EG in imaging, genome sequencing) |
Year(s) Of Engagement Activity | 2014,2015,2016,2017,2018,2019 |
URL | http://www.ukbiobank.ac.uk |